يعرض 1 - 10 نتائج من 197 نتيجة بحث عن '"Belloso, Waldo"', وقت الاستعلام: 1.33s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية

    المصدر: Park , H , Tarpey , T , Liu , M , Goldfeld , K , Wu , Y , Wu , D , Li , Y , Zhang , J , Ganguly , D , Ray , Y , Paul , S R , Bhattacharya , P , Belov , A , Huang , Y , Villa , C , Forshee , R , Verdun , N C , Yoon , H A , Agarwal , A , Simonovich , V A , Scibona , P , Burgos Pratx , L , Belloso , W , Avendaño-Solá , ....

    وصف الملف: application/pdf

  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية

    المساهمون: INM005 Study Group

    المصدر: EClinicalMedicine Vol.34, 100843, 2021

    وصف الملف: application/pdf

    العلاقة: Lopardo, G., et al. RBD-specific polyclonal F(ab )2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease : a randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial [en línea]. Postprint del artículo publicado en: EClinicalMedicine. 2021, 34 (100843). doi:10.1016/j.eclinm.2021.100843. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11639Test; https://repositorio.uca.edu.ar/handle/123456789/11639Test; https://doi.org/10.1016/j.eclinm.2021.100843Test

  6. 6
    دورية

    المؤلفون: Belloso, Waldo H.

    المصدر: Therapeutic Innovation and Regulatory Science; 20240101, Issue: Preprints p1-8, 8p

  7. 7
  8. 8
    دورية أكاديمية

    المساهمون: Clinicum, Department of Medicine, Infektiosairauksien yksikkö, HUS Inflammation Center

    وصف الملف: application/pdf

    العلاقة: This work was supported by the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases [UM1 AI 068641, UM1-A1120197]: the Department of Bioethics at the NIH Clinical Center: the National Cancer Institute: the National Heart, Lung, and Blood Institute; the National Institute of Mental Health; the National Institute of Neurological Disorders and Stroke; and the National Institute of Arthritis and Musculoskeletal Disorders. Financial support for START was also provided by the French Agence Nationale de Recherches sur le SIDA et les Hepatites Virales (ANRS); the Federal Ministry of Education and Research; the European AIDS Treatment Network (NEAT): the National Health and Medical Research Council; and Medical Research Council and National Institute for Health Research. Six pharmaceutical corn panics (AbbVie, Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV Healthcare, Janssen Scientific Affairs, LLC, and Merck Sharp and Dohme Corp.) donate antiretroviral drugs to START. The authors were also supported by the National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK100272, P01 DK056492 and R01 DK112258 to CW] and the National Institute on Drug Abuse [K24 DA035684, R01 DA026770 to GML].; Achhra , A C , Mocroft , A , Ross , M , Ryom-Nielson , L , Avihingsanon , A , Bakowska , E , Belloso , W , Clarke , A , Furrer , H , Lucas , G M , Ristola , M , Rassool , M , Ross , J , Somboonwit , C , Sharma , S , Wyatt , C & INSIGHT START Study Grp 2017 , ' Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial ' , International Journal of Antimicrobial Agents , vol. 50 , no. 3 , pp. 453-460 . https://doi.org/10.1016/j.ijantimicag.2017.04.021Test; ORCID: /0000-0001-5115-2811/work/40580735; 85027254683; f31c9579-4d4d-4d2d-a1a6-ae45e335c825; http://hdl.handle.net/10138/298136Test; 000408686800024

  9. 9
    دورية أكاديمية

    المساهمون: National Institute of Allergy and Infectious Diseases

    المصدر: Clinical Trials ; volume 17, issue 1, page 3-14 ; ISSN 1740-7745 1740-7753

  10. 10
    دورية أكاديمية